IL10 and inflammatory bowel disease: At an oral dose of 0.2 mg/kg, found to prevent and improve IBD and colitis-associated cancer treatments, reduce the mRNA expression of cytokines (IL-1β, IL-10 and 17), and be effective in the therapy of IBD